摘要
小细胞肺癌(SCLC)是恶性程度很高的肿瘤,其治疗也是肺癌治疗领域中的难点,因而SCLC长期生存率很低。近年来更多新药物、新方案分别用于SCLC一线化疗、二线化疗及分子靶向治疗的各期临床研究,尽管很多仍有待于深入研究和探索,但其治疗研究将为SCLC进一步联合化疗提供更多新的治疗策略和选择方案,由此提高患者生存率。
Small cell lung cancer（SCLC）is a highly malignant tumor,and it′s treatment is difficult in the field of lung cancer,so long-term survival of SCLC is very low.In recent years,more new drugs,new methods are used as the first-line chemotherapy for SCLC,the second-line chemotherapy and molecular targeted therapy in all clinical research stages.Although many points need to be in-depth studied and explored the treatment research of SCLC will provide more new chemotherapy treatment strategies and options,which may improve patient′s survival rate.
出处
《医学综述》
2011年第4期536-539,共4页
Medical Recapitulate
关键词
小细胞肺癌
一线化疗
二线化疗
分子靶向治疗
Small cell lung cancer
The first-line chemotherapy
The second-line chemotherapy
Molecular target therapy
